MIMaria Ileninova

Maria Ileninova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Ileninova has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Region‐ and Time‐Dependent Gene Expression Responses to Siponimod, Atorvastatin and Methylprednisolone After Spinal Cord Injury

    by Katarina Kiss Bimbova, Alexandra Kisucka, Tomas Kuruc, Maria Ileninova, Karolina Kucharova, Lenka Ihnatova, Maria Bacova, Martina Magurova, Nadezda Lukacova

    Traumatic spinal cord injury (SCI) triggers a secondary injury cascade in which microglia, infiltrating macrophages and astrocytes influence tissue degeneration and repair. These responses are dynamic and region‐dependent, yet the comparative effects of anti‐inflammatory therapies remain unclear. We evaluated siponimod, atorvastatin and methylprednisolone after Th9 compression injury in rats. Gene expression was assessed by quantitative RT‐PCR in rostral, lesion and caudal spinal cord segments at 2 and 6 weeks postinjury. At 2 weeks, all treatments reduced microglia/macrophage‐associated and inflammatory transcripts, particularly rostrally, as shown by reduced Iba1 and iNOS expression. Siponimod and atorvastatin also decreased IL‐1β rostrally, whereas siponimod was associated with region‐specific increases in inflammatory markers at the lesion site and caudally. Siponimod most consistently increased microglia/macrophage‐associated transcripts linked to immunoregulatory and reparative responses caudally, including IL1rn, TGF‐β, SOCS3 and IL4Rα. It also reduced selected inflammatory astrocyte‐associated markers and increased transcripts linked to repair‐related processes, while atorvastatin and methylprednisolone showed mixed effects. At 6 weeks, none of the treatments consistently suppressed pro‐inflammatory microglia/macrophage‐associated markers. Siponimod was associated with elevated transcripts linked to immunoregulatory and repair‐related processes, together with region‐dependent increases in inflammatory markers. Astrocyte‐associated reactivity markers were largely normalised, whereas remodelling‐associated transcripts were altered. Treatments induced modest changes in neuronal/axonal and myelin‐associated transcripts, predominantly rostrally, without significant functional improvement. Overall, these interventions differentially modulated microglia/macrophage‐ and astrocyte‐associated gene expression, with siponimod producing the broadest, but mixed and region‐dependent, gene‐expression pattern. These findings highlight the regional and stage‐dependent complexity of glial and inflammatory gene expression after pharmacological treatment of SCI.

  • Postinjury Carnosine Treatment Prevents Neurotrophic Factor Decline in Denervated Muscle and Spinal Cord After Traumatic Injury

    by Karolina Kucharova, Tomas Kuruc, Martina Magurova, Lenka Ihnatova, Maria Ileninova, Alexandra Kisucka, Jan Galik, Nadezda Lukacova

    Local intraspinal or intramuscular administration of brain‐derived or glial cell line‐derived neurotrophic factors (BDNF, GDNF) is known to protect neural tissue after traumatic spinal cord injury (SCI). In this study, we investigated whether oral supplementation with antioxidant carnosine, a natural dipeptide, could stimulate endogenous production of these neuroprotective molecules within the neural and muscle microenvironment 6 weeks after SCI. We assessed the effects of 6‐week carnosine treatment in female Zucker rats, administered either before (CB‐I) or after injury (CA‐I). The impact of thoracic SCI and carnosine treatment was evaluated in in /active microenvironments of fore limb and hind limb muscles, along with their corresponding innervation regions. To better understand how carnosine treatment affects the neural microenvironment, we analysed mRNA expression levels of neurotrophic factors and their receptors. We also examined molecules that may indicate which cell types are involved in producing or responding to BDNF or GDNF in the spinal cord. Six weeks after thoracic SCI, we observed better locomotor recovery in CA‐I compared to CB‐I treated rats. In the hind limb, posttraumatic carnosine treatment prevented SCI‐induced reductions in BDNF and GDNF protein levels. Additionally, this treatment blocked the SCI‐induced reduction of GDNF protein levels and the oligodendrocyte‐specific gene Olig2 in the lumbar and cervical spinal cord segments. Interestingly, the postinjury treatment elevated the gene expression in BDNF receptor‐ and astrocyte‐specific genes in the cervical segments. The finding that carnosine may prevent BDNF and GDNF declines in denervated hind limb muscles positions this dipeptide as a promising candidate for inclusion in future combination therapies.

  • Open Access

    Endurance training mitigates obesity-induced hippocampal impairment by enhancing neurotrophin signalling, synaptic plasticity, and cellular responses in a female rat model

    by Tomáš Kuruc, Karolína Kuchárová, Alexandra Kisucká, Mária Ileninová, Lenka Ihnátová, Katarína Kiss Bimbová, Martina Magurová, Ján Gálik, Nadežda Lukáčová

  • Open Access

    PHARMACOLOGICAL EFFECT OF THREE CLINICALLY APPROVED ANTI-INFLAMMATORY DRUGS ON REACTIVE ASTROGLIOSIS IN SUBACUTE AND CHRONIC PHASE AFTER TH9 COMPRESSION

    by Nadezda Lukacova, Katarina Kiss Bimbova, Alexandra Kisucka, Maria Bacova, Maria Ileninova, Tomas Kuruc, Martina Magurova, Jan Galik

  • Open Access

    THE EFFECT OF SUBPIAL DELIVERY OF CHONDROITINASE ABC ON REGULATING PI3K/AKT SIGNALING PATHWAY AFTER SCI

    by Alexandra Kisucka, Katarina Kiss Bimbova, Maria Bacova, Maria Ileninova, Tomas Kuruc, Martina Magurova, Jan Galik, Nadezda Lukacova